Intelligence Feed event · Equity · 2026-09-03

    Nxera Pharma Receives $8.6M Milestone from Eli Lilly Subsidiary Centessa

    Question

    Nxera Pharma Receives $8.6M Milestone from Eli Lilly Subsidiary Centessa

    Direct answer

    Nxera Pharma announced that it has achieved a late-stage clinical milestone under its partnership with Centessa Pharmaceuticals, a subsidiary of Eli Lilly and Company. The progression triggers an $8.6 million cash milestone payable to Nxera. The milestone centers on development advancements within the selective orexin receptor 2 (OX2R) agonist candidate program. Nxera confirmed that it will recognize the $8.6 million proceeds directly in its third-quarter 2026 financial results.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-03
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Nxera Pharma Receives $8.6M Milestone from Eli Lilly Subsidiary Centessa”, revision 1, evidence through 2026-09-03. https://marketontology.com/market-events/2026-09-03/nxera-pharma-receives-8-6m-milestone-from-eli-lilly-subsidiary-centessa-98c6b7

    EQUITY
    Nxera Pharma Receives $8.6M Milestone from Eli Lilly Subsidiary Centessa
    Nxera Pharma announced that it has achieved a late-stage clinical milestone under its partnership with Centessa Pharmaceuticals, a subsidiary of Eli Lilly and Company. The progression triggers an $8.6 million cash milestone payable to Nxera. The milestone centers on development advancements within the selective orexin receptor 2 (OX2R) agonist candidate program. Nxera confirmed that it will recognize the $8.6 million proceeds directly in its third-quarter 2026 financial results.
    LLY
    Impact
    55
    SEP 3
    SIG
    85%
    LLY
    Nxera Pharma Receives $8.6M Milestone from Eli Lilly Subsidiary Centessa
    Nxera Pharma announced that it has achieved a late-stage clinical milestone under its partnership with Centessa Pharmaceuticals, a subsidiary of Eli Lilly and Company. The progression triggers an $8.6 million cash milestone payable to Nxera. The milestone centers on development advancements within the selective orexin receptor 2 (OX2R) agonist candidate program. Nxera confirmed that it will recognize the $8.6 million proceeds directly in its third-quarter 2026 financial results.
    → Clinical milestone progress on selective OX2R agonists de-risks Eli Lilly's pipeline assets in sleep and neurological disorder therapeutic indications.
    Impact
    Nxera Pharma announced that it has achieved a late-stage clinical milestone under its partnership with Centessa Pharmaceuticals, a subsidiary of Eli Lilly and Company. The progression triggers an $8.6 million cash milestone payable to Nxera. The milestone centers on development advancements within the selective orexin receptor 2 (OX2R) agonist candidate program. Nxera confirmed that it will recognize the $8.6 million proceeds directly in its third-quarter 2026 financial results.
    Affected
    LLY
    Transmission
    Clinical milestone progress on selective OX2R agonists de-risks Eli Lilly's pipeline assets in sleep and neurological disorder therapeutic indications.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    LLYneuroscience pipeline development progressUp1-4wCentessa (Eli Lilly subsidiary) reaches late-stage development milestone on OX2R agonists

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month